ATE240725T1 - Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten - Google Patents

Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten

Info

Publication number
ATE240725T1
ATE240725T1 AT96908071T AT96908071T ATE240725T1 AT E240725 T1 ATE240725 T1 AT E240725T1 AT 96908071 T AT96908071 T AT 96908071T AT 96908071 T AT96908071 T AT 96908071T AT E240725 T1 ATE240725 T1 AT E240725T1
Authority
AT
Austria
Prior art keywords
rar
agents
contain
treatment
light
Prior art date
Application number
AT96908071T
Other languages
English (en)
Inventor
Graeme Findlay Bryce
Stanley Seymour Shapiro
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE240725T1 publication Critical patent/ATE240725T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96908071T 1995-03-31 1996-03-19 Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten ATE240725T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/414,242 US5807900A (en) 1995-03-31 1995-03-31 Method for identifying compounds having increased activity for the repair of skin photodamage
PCT/EP1996/001176 WO1996030009A2 (en) 1995-03-31 1996-03-19 Compositions for treatment of photodamaged skin comprising an rar-alpha antagonist and a multi-selective retinoid

Publications (1)

Publication Number Publication Date
ATE240725T1 true ATE240725T1 (de) 2003-06-15

Family

ID=23640589

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908071T ATE240725T1 (de) 1995-03-31 1996-03-19 Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten

Country Status (9)

Country Link
US (1) US5807900A (de)
EP (1) EP0817625B1 (de)
AT (1) ATE240725T1 (de)
AU (1) AU5146096A (de)
DE (1) DE69628287T2 (de)
DK (1) DK0817625T3 (de)
ES (1) ES2201175T3 (de)
PT (1) PT817625E (de)
WO (1) WO1996030009A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753627B1 (fr) * 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
FR2755011B1 (fr) * 1996-10-31 1998-11-20 Cird Galderma Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles et/ou les dommages aigus induits par les rayonnements u.v.
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU6513399A (en) * 1998-10-14 2000-05-01 Regents Of The University Of Michigan, The Prevention of uv-induced functional vitamin a deficiency through use of topically applied retinoid
DE19926779A1 (de) * 1999-06-11 2000-12-14 Basf Ag Verwendung von substituierten Vinyl-tetrahydronaphthalinen und Vinyl-benzotetrahydropyranen als Lichtschutzmittel
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
EP1280757B1 (de) 2000-05-02 2005-08-17 F. Hoffmann-La Roche Ag Gamma-selektive retinoide
EP1935869A1 (de) 2000-10-02 2008-06-25 F. Hoffmann-La Roche Ag Retinoide zur Behandlung von Emphysem
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
JP5986570B2 (ja) 2010-09-01 2016-09-06 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 筋修復および再生のための組成物および方法
WO2012076842A1 (en) * 2010-12-09 2012-06-14 University Of Durham Synthetic retinoids for control of cell differentiation
US8772273B2 (en) 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
WO2014145295A1 (en) 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Topical compositions for reducing aging effects
US20220339322A1 (en) 2019-10-02 2022-10-27 Inserm (Institut National De La Santé Et De La Researche Médecale) Use of retinoic acid receptor (rar) agonists for reversing, preventing, or delaying calcification of aortic valve

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
DE3853427T2 (de) * 1987-04-06 1995-12-14 Daltex Medical Sciences Inc Behandlung gealterter haut mit oraler 13-cis-retinsäure.
US5075333A (en) * 1987-08-19 1991-12-24 Hoffmann-La Roche Inc. Tetrahydronaphthalene and indane compounds useful for reversing the photo-damage in sun-exposed skin
AU2516092A (en) * 1991-08-23 1993-03-16 Ligand Pharmaceuticals, Inc. Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
CZ282548B6 (cs) * 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
CA2093577C (en) * 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids

Also Published As

Publication number Publication date
WO1996030009A2 (en) 1996-10-03
DK0817625T3 (da) 2003-09-15
ES2201175T3 (es) 2004-03-16
PT817625E (pt) 2003-10-31
DE69628287T2 (de) 2004-04-08
EP0817625B1 (de) 2003-05-21
EP0817625A2 (de) 1998-01-14
WO1996030009A3 (en) 1997-01-03
DE69628287D1 (de) 2003-06-26
US5807900A (en) 1998-09-15
AU5146096A (en) 1996-10-16

Similar Documents

Publication Publication Date Title
ATE240725T1 (de) Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
DE69512685T2 (de) Mittel zur verabreichung von wirksubstanzen an bzw. durch die haut
ATE364699T1 (de) Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen
AR003989A1 (es) Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica.
BR9611137A (pt) Composições e métodos para distribuição bucal de agentes farmacêuticos
HUP9800033A3 (en) Compositions for the treatment of dermatological disorders and methods for their use
DE69613840D1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
DE69530403T2 (de) Analogen des keratinozytenwachstumfaktors
PT920323E (pt) Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica
ATE192731T1 (de) Retinoid trienverbindungen und verfahren
ES2162051T3 (es) Preparacion dermatologica para tratar queratosis actinicas.
PT788361E (pt) Novas composicoes a base de uma mistura sinergetica entre pelo menos um ligante de vdr e um retinoide
ES2106057T3 (es) Liberacion de agentes.
AR004052A1 (es) Una composición cosmética o farmacéutica que comprende un agonista beta-adrenergico
BR0317805A (pt) Composição de cuidados oral ou pessoal, processo para produzir uma composição de cuidado oral, e, composição para aumentar a saúde, higiene ou aparência pessoais
GB2274777B (en) Synergistic combination of compounds having an antagonist effect on nk1 and on nk2 receptors
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
AR004326A1 (es) Utilizacion de al menos un antagonista de tnf-alfa, composicion cosmetica, farmaceutica o dermatologica que contiene dicho antagonista y procedimiento detratamiento cosmetico empleando dicho antagonista.
DE69519933D1 (de) Prostaglandinanaloga zur oralen oder vaginalen verabreichung in der routinebehandlung des dritten stadiums der geburtswehen
MX9804874A (es) Metodo y material para terapia capilar.
ATE187157T1 (de) Trizyclische retinoidverbindungen verfahren zu ihrer herstellung und verwendung
BRPI0417692A (pt) uso de uma composição, método de redução dos efeitos do estresse mediado psicologicamente na pele de um ser humano ou animal, composição, suplemento nutritivo, composição cosmética, e, método para identificar um composto capaz de reduzir os efeitos e método de produção de uma composição para a redução dos efeitos, do estresse mediado psicologicamente sobre a pele de um ser humano ou animal
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
DE59001925D1 (de) Mittel zur nagel-, haut- und haarpflege.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0817625

Country of ref document: EP